ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.09) per share and revenue of $15.46 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ARS Pharmaceuticals Stock Up 0.8 %

ARS Pharmaceuticals stock opened at $11.53 on Wednesday. ARS Pharmaceuticals has a 52-week low of $7.55 and a 52-week high of $18.51. The firm has a fifty day moving average of $11.98 and a 200-day moving average of $13.04. The firm has a market capitalization of $1.12 billion, a P/E ratio of -22.61 and a beta of 1.03.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the transaction, the director now directly owns 210,346 shares in the company, valued at $2,589,359.26. This represents a 19.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 149,600 shares of company stock worth $1,726,516 in the last ninety days. 40.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SPRY. Raymond James increased their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 price target for the company. Leerink Partners raised their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Finally, Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price target for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.